Valiant Thoracic Stent Graft With the Captivia Delivery System in the Treatment of Descending Thoracic Aortic Diseases (VALIANT CAPTIVIA France)
Launched by MEDTRONIC CARDIOVASCULAR · Jan 23, 2013
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
Data regarding the use under routine practice of thoracic aortic stent grafts in France are expected by the French National Authority for Health (HAS). Therefore, in its opinion report from December 22, 2009, HAS makes the maintenance of reimbursement approval of each stent graft dependent on the presentation of results of a specific follow-up study carried out in a cohort of patients representative of the French population treated under real-life conditions of use. This prospective cohort study must involve patients implanted after registration on the LPPR (List of Products and Services qu...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Any patient requiring placement of the Valiant Thoracic Stent Graft for the treatment of a disease of his/her descending thoracic aorta.
- • Patient or holder of parental authority not opposed to the collection and release of the personal information required by the study.
- • Patient or holder of parental authority has consented for study participation and the Medtronic approved Data Release Form has been signed and personally dated by patient or holder of parental authority and by the investigator.
- Exclusion Criteria:
- • Patient in whom clinical follow-up will not be possible i.e. patient not able to come back for follow-up visits (ex. patient living abroad).
- • Prior implantation of a thoracic stent graft.
About Medtronic Cardiovascular
Medtronic Cardiovascular is a leading global healthcare technology company dedicated to transforming patient care through innovative medical solutions. With a focus on cardiovascular health, Medtronic develops advanced devices and therapies that address a wide range of heart and vascular conditions. Committed to clinical excellence and patient outcomes, the company conducts rigorous clinical trials to evaluate the safety and efficacy of its products, ensuring they meet the highest regulatory standards. Medtronic Cardiovascular strives to enhance the quality of life for patients worldwide while advancing the field of cardiovascular medicine through research and development.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toulouse, , France
Créteil, , France
Limoges, , France
Marseille, , France
Paris, , France
Toulouse, , France
Paris, , France
Marseille, , France
Saint Priest En Jarez, , France
Le Plessis Robinson, , France
Saint Martin D'hères, , France
Amiens, , France
Bordeaux, , France
La Tronche, , France
Le Chesnay, , France
Marseille, , France
Villeurbanne, , France
Patients applied
Trial Officials
Hervé Rousseau, MD, PhD
Principal Investigator
CHU Rangueil, 1 Avenue Jean Poulhes, TSA 50 032, 31059 TOULOUSE Cedex 9, FRANCE
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials